A RARE CAUSE OF PITUITARY APOPLEXY: CABERGOLINE THERAPY.
Acta Endocrinol (Buchar)
; 14(1): 113-116, 2018.
Article
in En
| MEDLINE
| ID: mdl-31149244
Pituitary apoplexy (PA) is a life-threatening clinical syndrome. Dopamine receptor agonists are the drugs of choice in the treatment of prolactinomas. The use of cabergoline is reported to cause an increased risk of PA, particularly in macroprolactinomas of cystic nature. In this report, we present a patient with a cystic macroprolactinoma who developed PA on the 16th week of cabergoline treatment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Acta Endocrinol (Buchar)
Year:
2018
Document type:
Article
Affiliation country:
Turkey
Country of publication:
Romania